Acer Reports Q2'26 Revenues at NT$85.30 Billion, the highest Q2 in 13 years, up 28.2% Year-on-year

Acer Reports Q2'26 Revenues at NT$85.30 Billion, the highest Q2 in 13 years, up 28.2% Year-on-year

TAIPEI, July 10, 2026 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced its consolidated revenues for June at NT$27.82 billion with 6.3% growth month-on-month. Preliminary consolidated revenues for Q2'26 reached NT$85.30 billion, the highest Q2 since...

GreenTree Hospitality Group Ltd. Reports First Quarter of 2026 Financial Results

GreenTree Hospitality Group Ltd. Reports First Quarter of 2026 Financial Results

Total revenues decreased by 14.0% year over year to RMB227.7 million (US$33.0 million) [1] . Income from operations was RMB28.7 million (US$4.2 million) [1] compared to RMB11.3 million for the first quarter of 2025. Net income was RMB14.0 million...

Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately $436 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Over 283 Million WLD Tokens

Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately $436 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Over 283 Million WLD Tokens

Eightco treasury composition as of June 24, 2026: $90M OpenAI equity (indirect), $18M Beast Industries equity, 16,278 ETH, 283 million WLD holdings, and $149M cash and equivalents, totaling approximately $436 million Worldcoin token (WLD) now listed...

Colt DCS Reports 27% Reduction in Greenhouse Gas Emissions

Colt DCS Reports 27% Reduction in Greenhouse Gas Emissions

Delivered 27% reduction in greenhouse gas emissions in Scope 1, 2 (market based) and 3 compared to 2019 base year Achieved 100% renewable electricity in Scope 2 and 90% renewable share of total energy consumption (Scopes 1, 2 and 3). Advanced Global...

Trip.com Group Limited Reports Unaudited First Quarter of 2026 Financial Results

Trip.com Group Limited Reports Unaudited First Quarter of 2026 Financial Results

SINGAPORE, June 25, 2026 /PRNewswire/ -- Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) ("Trip.com Group" or the "Company"), a leading global one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours,...

LEIFRAS Co., Ltd. Reports Financial Results for the First Quarter of Fiscal Year 2026

LEIFRAS Co., Ltd. Reports Financial Results for the First Quarter of Fiscal Year 2026

Record High Revenue, Adjusted Income from Operations, and Net Income, Up 10.0%, 1.0%, and 1.5% Year-over-Year , Respectively [1] TOKYO, June 19, 2026 /PRNewswire/ -- LEIFRAS Co., Ltd. (Nasdaq: LFS) (the "Company" or "Leifras"), a sports and social...

Waterdrop Inc. Reports First Quarter 2026 Unaudited Financial Results, Q1 Net Revenue Up 64.8% Year-over-Year

Waterdrop Inc. Reports First Quarter 2026 Unaudited Financial Results, Q1 Net Revenue Up 64.8% Year-over-Year

BEIJING, June 16, 2026 /PRNewswire/ -- On June 16, 2026, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with positive social impact, today announced its unaudited financial results for the...

Uxin Reports Unaudited Financial Results for the Quarter Ended March 31, 2026

Uxin Reports Unaudited Financial Results for the Quarter Ended March 31, 2026

BEIJING, June 16, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), China's leading used car retailer, today announced its unaudited financial results for the quarter ended March 31, 2026. Highlights for the Quarter Ended...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc...

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

CAMBRIDGE, Mass. and TAIPEI, June 11, 2026 /PRNewswire/ -- Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 19
  • menu
    menu